Overexpression of CDC91L1 (PIG-U) in bladder urothelial cell carcinoma: Correlation with clinical variables and prognostic significance

BJU International

Volumn 101, Issue 1, 2008, Pages 113-119

  Shen, Yi Jun ^a   Ye, Ding Wei ^a   Yao, Xu Dong ^a   Trink, Barry ^b   Zhou, Xiao Yan ^a   Zhang, Shi Lin ^a   Dai, Bo ^a   Zhang, Hai Liang ^a   Zhu, Yao ^a   Guo, Zhongmin ^b   Wu, Guojun ^b   Nagpal, Jatin ^b  

^a FUDAN UNIVERSITY   (China)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bladder neoplasms; Glycosylphosphatidylinositols; Prognosis; Progression; Quantitative real time PCR; Recurrence

Indexed keywords

BIOLOGICAL MARKER; CELL DIVISION CYCLE 91 LIKE 1; MESSENGER RNA; PHOSPHATIDYLINOSITOL GLYCAN CLASS U; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CANCER; BLADDER CARCINOMA; BLADDER TUMOR; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; UROTHELIUM;

ACYLTRANSFERASES; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 36849088622     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07192.x     Document Type: Article

References (20)

1. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J Clin 2005 55 : 10 30
2. Li LD, Rao KQ, Zhang SW et al. Statistical analysis of data from 12 cancer registries in China, 1993-1997. Zhong Guo Zhong Liu 2002 11 : 497 508
3. Shanghai municipal center for disease control and prevention. Incidences of malignant tumors of city Shanghai in the year 2002. Tumor 2006 26 : 496
4. Malats N, Bustos A, Nascimento CM et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 2005 6 : 678 86
5. Latif Z, Watters AD, Dunn I, Grigor KM, Underwood MA, Bartlett JM. HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer 2003 89 : 1305 9
6. Ye DW, Zheng JF, Qian SX, Ma YJ. Correlation between the expression of oncogenes Ras and c-erbB-2 and the biological behavior of bladder tumors. Urol Res 1993 21 : 39 43
7. Kiyoshima K, Oda Y, Kinukawa N, Naito S, Tsuneyoshi M. Overexpression of laminin-5 gamma2 chain and its prognostic significance in urothelial carcinoma of urinary bladder: association with expression of cyclooxygenase 2, epidermal growth factor receptor [corrected] and human epidermal growth factor receptor [corrected]. Hum Pathol 2005 36 : 522 30
8. Komhoff M, Guan Y, Shappell HW et al. Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol 2000 157 : 29 35
9. Hernandez S, Lopez-Knowles E, Lloreta J et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 2006 24 : 3664 71
10. Pagliaro LC, Keyhani A, Williams D et al. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol 2003 21 : 2247 53
11. Winquist E, Moore M, Chi KN et al. A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. Urol Oncol 2005 23 : 143 9
12. Hussain M, Petrylak D, Dunn R et al. Trastuzumab (T), Paclitaxel (P), Carboplatin (C), and Gemcitabine (G) in advanced HER2-positive urothelial carcinoma: results of a multi-center Phase II NCI trial. J Clin Oncol 2005 23 (Suppl. 4507
13. Martinez-Torrecuadrada J, Cifuentes G, Lopez-Serra P, Saenz P, Martinez A, Casal JI. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation. Clin Cancer Res 2005 11 : 6280 90
14. Vecchione A, Sevignani C, Giarnieri E et al. Inactivation of the FHIT gene favors bladder cancer development. Clin Cancer Res 2004 10 : 7607 12
15. Hong Y, Ohishi K, Kang JY et al. Human PIG-U and yeast Cdc91p are the fifth subunit of GPI transamidase that attaches GPI-anchors to proteins. Mol Biol Cell 2003 14 : 1780 9
16. Ikezawa H. Glycosylphosphatidylinositol (GPI)-anchored proteins. Biol Pharm Bull 2002 25 : 409 17
17. Guo Z, Linn JF, Wu GJ et al. CDC91L1 (PIG-U) is a newly discovered oncogene in human bladder cancer. Nat Med 2004 10 : 374 81
18. Ho JC, Cheung ST, Patil M, Chen X, Fan ST. Increased expression of glycosyl-phosphatidylinositol anchor attachment protein 1 (GPAA1) is associated with gene amplification in hepatocellular carcinoma. Int J Cancer 2006 119 : 1330 7
19. Wu G, Guo Z, Chatterjee A et al. Overexpression of glycosylphosphatidylinositol (GPI) transamidase subunits phosphatidylinositol glycan class T and/or GPI anchor attachment 1 induces tumorigenesis and contributes to invasion in human breast cancer. Cancer Res 2006 66 : 9829 36
20. Schultz IJ, Kiemeney LA, Witjes JA et al. CDC91L1 (PIG-U) mRNA expression in urothelial cell carcinomas. Int J Cancer 2005 116 : 282 4